(P137) Midlevel Providers in Radiation Oncology and Their Role in Brachytherapy

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

With the increasing patient population in the oncology world and advancing technologies in radiation oncology in particular, there is an increasing need for assistance in providing high-quality care.

Amy Hacker-Prietz, MS, PAC, Joseph Herman, MSc, MD; Johns Hopkins University

Background: With the increasing patient population in the oncology world and advancing technologies in radiation oncology in particular, there is an increasing need for assistance in providing high-quality care. In the setting of radiation oncology, brachytherapy has broadened its scope over the last decade, and assistance with procedure-based aspects of implementing brachytherapy has increased in demand. The implementation of nonphysician practitioner roles, such as midlevel providers and physician assistants, can provide an improvement in the workflow of brachytherapy procedures. Physician assistants can perform procedures under a license agreement with their attending physician, once well trained and experienced, as part of the delegation with the Board of Physicians. This allows midlevel providers to set patients up for brachytherapy procedures, construct equipment devices, insert appropriate devices, assess applicator localization images, and assess treatment fields, all prior to the physician being present to initiate treatment. Physician assistants also have the ability to charge for brachytherapy services while freeing up physician time to focus on treatment planning and target delineation, as well as other clinic demands.

Methods: Review of literature of midlevel provider roles in radiation oncology, personal experience, and investigation of billing reimbursement for brachytherapy procedures for midlevel providers.

Results: Physician assistant billing allows for 85% to 100% of the physician fee schedule, depending on the payer. Midlevel providers qualify to bill for Current Procedural Terminology (CPT) codes, including catheter placement and device placement for brachytherapy procedures. These advanced duties, performed under the supervision of a radiation oncologist, can be incorporated into delegation agreements with procedure logs for brachytherapy procedures, including vaginal/gynecological, endorectal, skin, interoperative, prostate, and bile duct sites. At our institution, we use midlevel providers for the GI group, which consists of intraoperative, endorectal, skin, and bile duct procedures, which includes simulation and treatment setup. Quite frequently, these procedures can take considerable time, therefore freeing up the physician during certain time points of the brachytherapy process.

Conclusion: The emergent role of midlevel providers has been increasing in awareness and utilization and is promising to assist in improving patient treatment flow, provider workflow, and overall patient care and patient experience. Integrating physician assistants with onsite training experience into brachytherapy procedures can be cost- and time-effective for radiation oncology departments. There is now more of a demand for experienced providers for brachytherapy procedures, and midlevel providers, such as physician assistants, can be well trained, experienced, and specialized to help fill the deficit. In an academic setting, establishing the role of physician assistants in brachytherapy technology is not meant to minimize the experience of the resident but to act as an additional enhancement to the teaching, allowing more time for the procedure-based aspect while the physicians will remain the integral part of the prescribing of treatment.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content